Sodium–glucose cotransporter 2 (SGLT2) inhibitors, which inhibit the reabsorption of filtered glucose in the kidneys to increase urinary glucose excretion, were recently developed and proposed as novel anti‐hyperglycemic agents for treating type 2 diabetes (Chao, 2014). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.